<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 339 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page338.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=339">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 339 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 339</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=339"><img src="../thumb/339.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>302 / 2020-04                                                      Endocrine System - 19.6.1 / 19.6.2
   Drug interactions: Enhanc.insul.bld.sugar low eff., clear poss.  ord./thrombophlebit., curr./hist.of arter.thrombo-embol.dis., por-  headaches/ SLE/epilep./asthma/otoscleros., incr. endometr. Ca/
   incr.by microsom.enzym.induc., metabol.of other drugs poss.inter-  phyr., CV dis.prev., childr.  hyperplas./breast & ovar.Ca/VTE/ CAD/ischaem.stroke risk relat.to
   fer.with, activ.of OC’s incr.  Side-effects: CNS/psychiatr.disords., chorea, GI disturbs., con-  longt.oestrog., thromboembol. disord.risk incr.with prolong. immobi-
   PROVIRON, Bayer              tact lens intol., chloasma/ melasma, erythema multiforme/nodo-  lisat./ maj.trauma or surg., withdr.bef. plann. surg.& dur.hospitalisat.
                                sum, rash, alopec., hirsut., breakthrough bleed., uter. leiomyoma,
                                                              aft.trauma advis., incr. circulat.total thyroid hormone/ corticoster./
   Mesterolone.                 candidias., cervic.discharg., breast tendern./enlargem/Ca, weight   sex hormones, incr.risk of probable dement.in pts. &gt;65 start ther.,
   Indications: Male declin.physic.& ment.activ., potency disturb.,   chang., carbohydr. tol.decr., oed., libido incr./decr., contact. sensiti-  card./ren.dysfunct., discont. immed.in pres.of ven.or arter. thrombo-
   infertil., hypogonad.        sat., oestrog.depend.neoplasms, ven. thrombo-embol., stroke, MI,   embol. disords./ arter.dis./jaund./liv.funct.deteriorat./ signif. BP incr./
   (S5) TABS. B/21.7/137.       cholestat.juand., gallbladd. dis., porphyr.aggrav., dement.  new onset migraine-type headache & pregn., lact.intol.
   757950-019: 25 mg, 20, R282,73  Special precautions: Eval.benef.vs.risk of ther. & assess regul.,   Interactions: Metabol.incr.by drugs.induc.drug-metabol. enzymes
   757950-027: 25 mg,100, R1 413,78  breast screen pract.to implem., supplem.with progestog. in women   (cytochrome P450 enzymes) eg. phenobarbit./ phenytoin/car-
   Dosage: Decr.physic.activ./potency disturb: 1 tab 3xdly then   with intact uterus, compl.medic.hist.& exam.bef.&.dur.ther., consid.  bamezap./anti-infect./ rifampic./rifabutin/nevirapine & efavirenz.,
   1 tab 1-2xdly x several wks./ mnths. Rep.if necess.  low.dos.& short.durat., regul.breast exam. recomm., undiagn./per-  St John’s Wort induc.metabol.
   Hypogonad: 1 tab 3-4xdly. x several mnths., then 1 tab. 2-3xdly.  sist.vag.bleed., monit. caref. esp.in prev./pres.leiomyoma/endome-
   Oligozoospermia: 1 tab 2-3xdly for approx. 90 days. Combinat.  trios./ thrombo-embolit.disords/HF/hypertens./hepat./ ren.disords./  EVOREL, Janssen Pharmaceutica [P/S]
   therapy with gonadotroph. hormone exhibit.FSH activ.in simultan.  diab.mellit.with/without vasc. involvem/ cholelithias./migraine/sev.  ß-oestradiol.
   impair. gonadotroph.excret.  headache/ SLE/endometr. hyperplas./asthma/epilepsy/ otoscle-  Indications: Treat.sympt.assoc.with menopause due to menopaus.
   Contraindications: Ca.prostate.  ros./ gall bladd.dis./ oestrog.relat.jaund./ prurit., oestrog. depend.  cessat.of oestrog.product.& secret.or surg.ovary remov., oestrog.
   Special precautions: Male pts.only. Reg. prostat. exams.  tumour risk fact., discont.in liv. funct.deteriorat./BP incr./migr.-type   depend.post-menopaus. osteoporos.prevent. treatm.should not be
                                headache/ pregn., monit.with card./ren.dysfunct./ hypertriglyc-  contin.for more than 5 yrs.
                                eridaem., concom.progestogens low endometr. hyperplas.incid.&   (S4) PATCH. 30/21.8.1/0207, Z/21.8.1/339, 30/21.8.1/0208, 0209.
   19.6.2  Oestrogens           endometr.Ca risk., not for CV dis.prevent./contracept., incr.CV dis./   823007-006: 25 µg equiv.to 1,6 mg, 8, R194,07
                                                              810290-006: 50 µg equiv.to 3,2 mg, 8, R209,71
                                breast,endometr. & ovar.Ca/ven.thrombo-embol. risk, incr.dement.
          (See also 19.6.4)     risk report.in combin.oral HRT stud., VTE prophylax.follow.surg/pro-  823015-009: 75 µg equiv.to 4,8 mg, 8, R218,87
                                                              823023-001: 100 µg equiv.to 6,4 mg, 8, R228,64
   ESTRADOT (MDR Listing)       long. immobilisat., incr.oestrog./progest.metabol.poss. lead to decr.  Dosage: Apply to undamag. skin. Rotate applic. area. Change every
                                eff.& uter.bleed.chang., concom. prot.inhibits.
   CLIMARA, Bayer [P/S]         Drug interactions: Metabol.incr.by subst.induc. drug-metabol.  3-4 days. Init. with 3,2 mg indiv.in furth.treatm.cours. Admin.in a
                                                              cyclic manner, 3 wks. treat.(6 applic.) & 1 wk.without treat. Contin.
   Estradiol hemihydrate        enzymes specif.cytochrom P-450 enzymes, metabol.induc.by St   non-cycl.treatm.may be indic.in hysterectom. women.& if climacter.
   Indications: Estrog.replacem.in disords.due to natural menopause/  John’s Wort.  sympts.occur. dur. treatm.free wk. Maint: low.effect.dos.not exceed.
   surg. induc.menopause if for non carcinomatous dis., postmenopaus.   See also MDR page 86.  6,4 mg oestrad./24 hrs. Concom. progestogen. recomm.dur.12-14
   osteoporos. risk reduct.     ESTRO-PAUSE, AI Pharm Ltd [P/S]  consec.days of calend.mnth.dur.uninterrupt.ther.or dur.last 12-14
   (S4) PATCHES-50, [P/S] 29/21.8.1/0610  Oestradiol valerate.  i.e. start.on cycle days 8 or 10 of 21 day treatm cycle
   824631-005: 3,9 mg, 4 patches, R180,13  Indications: Hormon.replacem.therapy for menopaus.sympts.in   Contraindications: Known curr./past/susp. breast Ca, known/susp.
   (S4) PATCHES-100, [P/S] 29/21.8.1/0611  hysterectom.wom.   oestrog.depend.malign./ pre-malign.tumours, undiag.genit.bleed.,
   824658-019: 7,8 mg, 4 patches, R191,53   (S4) TABS. 29/21.8.1/0645, 0449.  pregn.& lactat., act.liv.dis./hist.thereof as long as liv.funct. test fail.
   Dosage: Apply patch to lower trunk once wkly. Do not apply to   822477-009: 1 mg, 28, R110,06  return.to norm., prev./curr.ven.thrombo-embol., known thrombophil.
   breasts. Rotate applic.sites, do not apply to oily, damag/irrit.sites,   822485-001: 2 mg, 28, R116,39  condits., act./ hist. arter. thrombo-embol.dis., endometrios., porphyr.
   apply immed.aft. open.       Dosage: 1-2 mg dly.accord.to sev.of sympts.& clinic.respons.  Side effects: Genit.candidias., hypersens., headache, dizzin.,
   Init.with low.dos.consid.high.dos.if necess. then est.low.effect.dos.   Contraindications: Fam./person.breast or genit. tract malign.  palpitat., GI disturbs.incl.abdom. pain, skin reacts., myalg./arthralg.,
   to contr.sympts. Unoppos. oestrog. ther.only to be used in hysterec-  neoplast.dis.hist., prev.thrombo-embol. disords., CV dis., kidn.dis.,   breast pain/ enlargem., metrorrhag., dysmenorrh., fluid retent. with
   tom. women. In all other cases admin.appropr. progestog. dos.x10-  thrombophlebit., undiagn. vag.bleed., herpes gestat., endometri-  oed., incr.weight, applicat.site reacts., breast / endometr.Ca, epilep.,
   12 days each mnth. In contin. treatm.init.progestog.at an arbitrar-  os., liv. impairm., jaund., sickle-cell anaem., persist.  itch. dur.prev.  arter./ven.thrombos., psych.disords., CVA, MI, DVT, migraine, pulm.
   ily select.time & rep. at 4 wk.interv. If cyclic. (3 wk.) treatm.chosen   pregn., otoscleros.that deteriorat.due to pregn. Relative C/I: Diab.  embol., cholelithias., angioed.
   admin.progestog. dur. last 10-12 days of cycle.  mellit., epilepsy, asthma, hypertens., depress., porphyr., fluid retent.   Warnings and special precautions: Reg.gynae. exam.&. bef.
   Osteoporosis risk reduct: Individ. Init.as soon as poss.aft.  states., pregn.& lactat.  init.ther., med./famil.hist.of ven./ arter. thrombophlebit./throm-
   menopause                    Side effects: Na & water retent., tend.& enlarg. breasts, li-  bo-embol.disords., eval. rep.breakthr.bleed/unexpect.vag.bleed
   Contraindications: Pregn., lactat., undiagn. abnorm. genit.bleed.,   bido chang., menstr.disords, withdr. bleed., vagin.disch., jaund.,   & chang. notic.dur.breast.exam., cons.benef./risk bef. init.ther.,
   suspect./known breast Ca, suspect./known premalign.condits./ma-  gallston., depress., CNS effs., palpitat., GI disturbs., epistax., hy-  leiomyoma, thromboembol. disord./ oestrog.depend.tumour risk
   lign.if sex. ster.influenc., pres./hist.of liv.tumours, ac.arterial disords   pertens., decr.gluc.& cont.lens tol., prem.clos.of epiphys. with   fact., hypertens., liv. disord., diab.mellit., cholelithias., migraine/
   thromboembol., act.DVT./thromboembol./ hist thereof.  large dos., skin reacts.  sev. headache, SLE, endometr.hyperplas.hist., epilep., mastopathy,
   Side effects: Lithogenic.of bile incr., abnorm. uter. bleed., loc.re-  Special precautions: Cyclic.progestrog.to prev. assoc. endometr.  otoscleros., Dubin Johns., Rotor syndr., card./ren.dysfunct./mild liv.
   acts., breast pain/tendern., GI disturbs., oed., chang.in body weight   proliferat.& conseq.Ca in post-menopaus. women not hysterecto-  funct.impairm., cholestat.jaund.hist., pre-exist. hypertriglyceridaem.,
   & libido, musc. cramps, headache, migraine, dizzin., uter. bleed. pat-  mis., discont.in pres. of migraine/ unusually sev.headaches, where   discont.in case of: jaund./liv. funct. deteriorat./signif.BP incr./new-
   tern chang., spott., worsen.porphyr., cholestat. jaund., incr.uter.leio-  thrombos. risk pres., if jaund.or rise in BP occurs, monit. liv.funct.  onset migraine-type headache/pregn., endometr. hyperplas. & Ca
   myomata size, alter. cervic. secret., chloasma.  in cases of mild chron.liv.dis., monit. pts.suffer.from condits.subj.  risk incr when admin.for prolong. periods to women with an intact
   Special precautions: Complete med.hist & examinat.bef.& reg.  to deteriorat. dur.pregn.  uterus, progestrog. as adjunct to prev. assoc.endometr. hyperplas.
   dur.ther., risk:benef. considerat. in pts.with venous thromboembol.  & Ca in postmenopaus.women with intact uterus, resid.endometri-
   risk fact, tempor.discont.dur.prolong.immobilisat., discont.immed.  ESTROFEM, Novo Nordisk [P/S]  os., incr.breast Ca risk, incr.ovar.Ca risk in hysterectom.women, incr.
   if contra-indicat.condits.appear/ suspect., incr.coron.heart dis.risk   Estradiol.  stroke/ coron.arter.dis./ven thrombo-embol.risk, recur. thromboem-
   shown with equine estrogen & medroxyprogesterone acet., addit.  (S4) TABS 1 mg, 34/21.8.1/0159.  bol./spontan.abort.family hist., cons. benef./risk with concom.anti-
   of progestogens to unoppos.estrog.ther. elimin. incr.endometr.hyper-  Indications: Oestrog.defic.sympts.in hysterectomis. pts, adjunct.in   coag., prolong. immobilisat., maj.trauma, discont.bef.plann.surg.&
   plas/Ca risk, incr.breast Ca risk in HRT over several yrs., incr.ovar.Ca   prevent.oestrog. defic. osteoporos.in postmenopaus.women.at high   not restart.until pt.mobilis., discont.if ven. thromboembol. devel.aft.
   risk report.in epidemiolog.study in pts.on long-term estrog. replacem.  risk of fut.fractures intol.of/ contra-indicat.for other medicin.products  init.ther., pt.to alert dr.of potent.thrombo-embol.sympt., incr.dement.
   ther., poss. intra-abdom. haemorrh. with benign & malign.liv.tumours,   893919-004: 1 mg, 28, R154,97  risk, not for contracept.use, do not apply on/near breasts, withdr.
   incr. dement.risk with conjug.equine estrog.-contain. preps if init.in   Dosage: 1 tab dly without interrupt.pref.at same time dly. Suffic.  ther.immed.if pregn.occurs, concom. lamotrigine,
   women &gt;65 yrs., discont.treatm.if migrain.or freq.& unusually sev.  progest.dos.add.for at least 12 days/ cycle in non-hysterectom.  Drug interactions: Meds.with high potent.for liv. enzyme induct.
   headaches/ rep.persist.skin irritat./clinic.signific.hyperten./ recurr.of   women.avoid. endometr.hyperplas.risk., eval.eff.aft.2-3 mnths. &   poss.interf. with act.of oestrog./ decr. effic., ritonavir/nelfinavir/
   cholestat.jaund.or prurit./incr.size of uter.myomas/endometrios.re-  switch to 2mg in case of insuffic.eff.  St John’s Wort may decr.eff./incr.vag.bleed., lamotrigine plasma
   activat.occurs, imp.liv.funct., endometrial assessm.in pres.of freq./  (S4) TABS 2 mg, J/21.8.1/214.  conc.poss.decr.
   persist.abnorm.uter.bleed., rule out prolactinoma if suspect., sun or   Indications: Oestrog.defic.sympts.in hysterectomis. pts, adjunct.
   UV expos.if tendenc.to chloasma, epilep., benign breast dis., asth-  in prevent.oestrog. defic. osteoporos.in postmenopaus.women.  FEMIGEL, Medi Challenge [P/S]
   ma, migraine, porphyr., otoscleros, SLE, chorea minor, non-hormon.  825883-008: 2 mg, 28, R168,92  Oestradiol
   contracept.precaut.if reqd.  Dosage:1 tab.dly.pref.at same time. Use low. effect. dos.  Indications: Oestrog.replacem.ther.for sympts.of nat./surg.
   Interactions: Clear.incr.by long.term treatm.with hepat.enzyme-  Contraindications: Breast Ca susp./hist., oestrog. depend.neop-  menopause.
   induc.drugs, lev.elev.by ac.alcoh. ingest.  las./susp., porphyr., ac./ chron. liv.dis./persist.liv.funct.abnorm., act.   (S4) GEL, 28/21.8.1/0600. 1,5 mg/2,5 g
                                thrombophlebit.,/ thrombo-embol.disords./cerebr. apoplex. hist., un-  819875-007: 80 g with met.pump., R198,20
   ESTRADOT, (AI Pharm) Novartis [P/S] &  diagn.vag.bleed., pregn.& lactat., prev. idiopath/curr.ven.thrombo-  Dosage: Applied top.to intact skin of approx.750 cm  (e.g. arms,
                                                                                     2
   Oestradiol.                  embol., act./prev. arter. thromboembol.dis, haemoglobinopathies,   shoulders, inner thigh) NOT on/near breasts/vulva.
   Indications: Oestrog.replacem.ther.for menopaus. sympt., reduc.  untreat. endometr. hyperplas., hypertens.  Usual start.dos:2,5 g (2 plunges) dly.on continual basis. Women with
   post-menopaus. osteoporos. risk  Side effects: Common: Depress., headache, abdom. pain/naus,   intact uterus to take recomm. progest.dos.dly.x12 days.
   (S4) TRANSDERM.PATCH, 37/21.8.1/0493, 0215, 0216, 0217,   leg cramps, breast tendern./ -enlargem./ -pain, oed., incr.weight. Un-  Contraindications: Pregn., known/suspect. breast/genit.tract Ca
   0218                         common: Abnorm. vis., ven,thromboembol., dyspeps., vomit., flatul./   or other oestrog.depend. neoplas., sev.hepat./ren./card.dis., porphyr.,
   706049-001: del.25 µg/day, 8, R180,21  bloat., cholelithias., rash/urticar. Unknown: Generalis. hypersens.  thrombos./thrombo-embol.disords., endometr. hyperplas., undiagn.
   706052-001: del.37,5 µg/day, 8, R180,21  reacts, deteriorat. of migraine/asthma, stroke, dizzin., diarrh., alopec.,   vag.bleed., not recomm.in childr.
   706053-001: del.50 µg/day, 8, R207,21  irreg. vag.bleed.in non-hysterectomis.women, incr. BP, MI, congest.  Side effects: Topic reacts., system.effs.
   706054-001: del.75 µg/day, 8, R207,21  heart dis., gall bladd.dis., chloasma, erythema multiforme/nodosum,   Special precautions: Compl.physic.& gynae. exam. bef.init.ther.&
   706055-001: del.100 µg/day, 8, R207,21  vasc. purpura, prurit., vag.candidias., malign./benign oestrog.-de-  rep.at reg.interv., incr.risk of endometr.Ca in women with intact uter.
   Dosage: Admin.as contin.ther. Do not apply to breasts.  pend.neoplasms, insomn., epilep., libido disord., probable dement.  theref. progesterone essent., mastopathy, breast Ca family hist.,
   Climact.sympts: Apply 2xwk. Init.with a 50 µg patch. Indiv.further   Warnings and special precautions: Incr. endometr. Ca/hyperp-  monit.BP, discont.if hypertens. develops, discont.4 wks.bef.surg.,
   accord.to needs. Maint.ther: Low.effect.dos.  las./patholog.condit.risk with longt. unoppos.oestrog.ther., compl.  cholelithias., endometrios.hist., gel to be applied by pt.herself.,
   Postmenopaus.osteoporos.prev: Init.with a 50 µg patch. Indiv.  physic./med./ fam. hist. bef.ther.init. & reg.exam.dur.treatm.,re-  skin contact with others esp.male partn.to be avoid. for 1 hr.aft.ap-
   further accord.to needs. Maint. ther: Low.effect.dos.  appraise risk-benefit ratio annually, contin.ther. exceed. 5 yrs.not   plic., avoid skin clean./ detergents & skin care products with high
   Contra-indications: Known/suspect.pregn., breastfeed., undi-  recomm., monit.of condits. pres./ past/ occur.dur.pregn.or prev.horm.  alcoh. cont. & keratolyt., concom.skin meds.which alt.skin product.
   agn.abnorm.vag.bleed., known/ suspect.breast/endometrium Ca,   treatm.eg uter. fibroids./endometrios./thromboembol.disord./ endo-
   breast Ca hist., oestrog.depend.neoplas., exist./prev.sev.hepat.   metr. hyperplas./oestrog.depend.tumour risk facts./ hypertens./liv.  PREMARIN, Pfizer [P/S]
   dis., hist./curr.ven.thrombo-embol., curr./hist.of thrombophil.dis-  dis./diab.mellit.with vasc. involvem./ cholelithias./migraine or sev.   Conjug.oestrog.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page338.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page334.html">334</a>&nbsp;&nbsp;&nbsp;<a href="page335.html">335</a>&nbsp;&nbsp;&nbsp;<a href="page336.html">336</a>&nbsp;&nbsp;&nbsp;<a href="page337.html">337</a>&nbsp;&nbsp;&nbsp;<a href="page338.html">338</a>&nbsp;&nbsp;&nbsp;<a href="page339.html">339</a>&nbsp;&nbsp;&nbsp;<a href="page340.html">340</a>&nbsp;&nbsp;&nbsp;<a href="page341.html">341</a>&nbsp;&nbsp;&nbsp;<a href="page342.html">342</a>&nbsp;&nbsp;&nbsp;<a href="page343.html">343</a>&nbsp;&nbsp;&nbsp;<a href="page344.html">344</a>
             </td>
             <td width="35%"><a href="page340.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page340.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
